Seattle Biomedical Research Institute

Ruprecht-karls-universitat Heidelberg

Walter and Eliza Hall Institute of Medical Research

Ruprecht-karls-universitaet Heidelberg

Ann-Kristin Mueller

Stefan H I Kappe

Kai-Uwe C Matuschewski

Alan E Cowman

Alexander Gerd Maier

Eva Morath

Kelley Van Buskirk

Mehdi Labaied

Ahmed Sayed Ibrahim Aly

Stefan HI Kappe

Kai-Uwe C Matuschewki

The present invention relates to peptides comprising at least one antigenic determinant or epitope of an apicomplexan Ferlin, Ferlin-like protein and/or another C2-domain containing protein for use as malaria vaccines. It further relates to compositions comprising said peptides and to the use of such compositions as malaria vaccines.

Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other C2-domain containing proteins

Method for inoculating a vertebrate host against malaria, by administering to the host a liveorganism that is genetically engineered to disrupt a liver-stage-specific gene function.

Live genetically attenuated malaria vaccine

The invention provides methods for inducing an immune response in a vertebrate host against a protozoan parasite, comprising administering to the host a live protozoan parasite that is genetically engineered to disrupt a stage-specific gene function that is required by the protozoan parasite to establish a secondary infection in the vertebrate host. Representative protozoan parasites belong to the phyla Apicomplexa and Kinetoplastida. The vertebrate host may be a mammal or a bird.

Live genetically engineered protozoan vaccine

Method for inoculating a vertebrate host against malaria, by administering to the host a liveorganism that is genetically engineered to disrupt a gene whose expression is up-regulated in liver stage parasites and whose function is not required for entry into hose hepatocytes.

Growing community of inventors

Dossenheim, Germany

Ann-Kristin Mueller